Facebook Linkedin RSS Twitter Youtube
Home 2023

Gout

Cancer Drug May Be Repurposed for Inflammatory Diseases
Cancer

Cancer Drug May Be Repurposed for Inflammatory Diseases

Amgen Vows to Fight Back as FTC Takes Aim at $27.8B Horizon Deal
Drug Discovery

Amgen Vows to Fight Back as FTC Takes Aim at $27.8B Horizon Deal

FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout
Industry News

FDA Approves First Fixed-Dose Combo Treatment for Hyperuricemia in Gout

Grünenthal to Buy Ex-Japan Global Rights to AstraZeneca’s Migraine Drug for Up to $302M
Drug Discovery

Grünenthal to Buy Ex-Japan Global Rights to AstraZeneca’s Migraine Drug for Up to $302M

CymaBay Licenses Out to Kowa U.S. Rights to Gout Candidate
Industry News

CymaBay Licenses Out to Kowa U.S. Rights to Gout Candidate

AstraZeneca Gout Candidate Succeeds in Three Phase III Trials
News

AstraZeneca Gout Candidate Succeeds in Three Phase III Trials

Takeda Buys URL Pharma for $800M to Acquire Gout Drug
Industry News

Takeda Buys URL Pharma for $800M to Acquire Gout Drug

BioCryst Closes $30M Financing Deal for Clinical Development of Gout Treatment
Industry News

BioCryst Closes $30M Financing Deal for Clinical Development of Gout Treatment

Servier Inks Deal with Xoma with $35M Up Front to Develop IL-1 Antibody
News

Servier Inks Deal with Xoma with $35M Up Front to Develop IL-1 Antibody

3SBio Acquires EnzymeRx’ Phase I-Stage Gout Therapy for $6.25M
News

3SBio Acquires EnzymeRx’ Phase I-Stage Gout Therapy for $6.25M

12Page 1 of 2
Copyright © 2023 Genetic Engineering & Biotechnology News. All Rights Reserved.